ViewRay to Participate in the 40th Annual J.P. Morgan Healthcare Conference

ViewRay, Inc. (NASDAQ: VRAY) announced its participation in the 40th Annual J.P.

Rhea-AI Summary

ViewRay, Inc. (NASDAQ: VRAY) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference, set for 10:30 a.m. Eastern Time on January 13, 2022. An audio webcast of the presentation will be available on ViewRay's investor website. ViewRay specializes in the MRIdian® MR-Guided Radiation Therapy System, designed to address specific challenges in radiation oncology, including issues related to high magnetic fields and radiation beams. More information can be found on their investor events page.

Argus Session date unavailable

-0.37% session move Open Argus

Details

News Market Reaction – VRAY

The recorded move for VRAY in the trading session of this news was -0.37%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CLEVELAND, Dec. 23, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced its participation in the 40th Annual J.P. Morgan Healthcare Conference.

ViewRay's management is currently scheduled to present at 10:30 a.m. Eastern Time on Thursday, January 13, 2022.  An audio webcast of the Company's presentation will be available on the "Financial Events and Webinars" portion of ViewRay's investor website at https://investors.viewray.com/events-and-presentations/upcoming-events

About ViewRay®

ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® MR-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

View original content:https://www.prnewswire.com/news-releases/viewray-to-participate-in-the-40th-annual-jp-morgan-healthcare-conference-301450548.html

SOURCE ViewRay, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is ViewRay's presentation at the J.P. Morgan Healthcare Conference?

ViewRay's presentation is scheduled for 10:30 a.m. Eastern Time on January 13, 2022.

Where can I watch the ViewRay presentation webcast?

The audio webcast will be available on the 'Financial Events and Webinars' section of ViewRay's investor website.

What is the primary focus of ViewRay's technology?

ViewRay focuses on the MRIdian® MR-Guided Radiation Therapy System, which addresses unique clinical challenges in radiation oncology.

What stock symbol is associated with ViewRay?

ViewRay is listed under the stock symbol VRAY.

What is unique about the MRIdian system from ViewRay?

The MRIdian system is built with a proprietary high-definition MR imaging system specifically designed to overcome issues like beam distortion and skin toxicity.